RU2640928C2 - Комбинация фульвовой кислоты и антибиотика для подавления роста бактерий, резистентных к множеству лекарственных средств, или лечения инфекций, вызванных ими - Google Patents

Комбинация фульвовой кислоты и антибиотика для подавления роста бактерий, резистентных к множеству лекарственных средств, или лечения инфекций, вызванных ими Download PDF

Info

Publication number
RU2640928C2
RU2640928C2 RU2014140227A RU2014140227A RU2640928C2 RU 2640928 C2 RU2640928 C2 RU 2640928C2 RU 2014140227 A RU2014140227 A RU 2014140227A RU 2014140227 A RU2014140227 A RU 2014140227A RU 2640928 C2 RU2640928 C2 RU 2640928C2
Authority
RU
Russia
Prior art keywords
fulvic acid
treatment
combination
bacteria
chd
Prior art date
Application number
RU2014140227A
Other languages
English (en)
Russian (ru)
Other versions
RU2014140227A (ru
Inventor
Стивен Уилльямс ЛЕЙВЕРС
Питер УОРН
Original Assignee
Нейтресин Юк Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейтресин Юк Лимитед filed Critical Нейтресин Юк Лимитед
Publication of RU2014140227A publication Critical patent/RU2014140227A/ru
Application granted granted Critical
Publication of RU2640928C2 publication Critical patent/RU2640928C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014140227A 2012-03-07 2013-03-06 Комбинация фульвовой кислоты и антибиотика для подавления роста бактерий, резистентных к множеству лекарственных средств, или лечения инфекций, вызванных ими RU2640928C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA201201683 2012-03-07
ZA2012/01683 2012-03-07
PCT/IB2013/051772 WO2013132444A1 (en) 2012-03-07 2013-03-06 Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria

Publications (2)

Publication Number Publication Date
RU2014140227A RU2014140227A (ru) 2016-04-27
RU2640928C2 true RU2640928C2 (ru) 2018-01-12

Family

ID=48142838

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014140227A RU2640928C2 (ru) 2012-03-07 2013-03-06 Комбинация фульвовой кислоты и антибиотика для подавления роста бактерий, резистентных к множеству лекарственных средств, или лечения инфекций, вызванных ими

Country Status (8)

Country Link
US (1) US9265744B2 (enExample)
EP (1) EP2822551B1 (enExample)
KR (1) KR20140135813A (enExample)
CN (1) CN104203227A (enExample)
IN (1) IN2014DN07194A (enExample)
MY (1) MY170829A (enExample)
RU (1) RU2640928C2 (enExample)
WO (1) WO2013132444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
CN109706195B (zh) * 2018-12-27 2022-04-08 齐齐哈尔龙江阜丰生物科技有限公司 颗粒型苏氨酸的生产工艺
CN111616358A (zh) * 2020-06-20 2020-09-04 田劭军 一种用于提高免疫力的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147635A1 (en) * 2008-06-05 2009-12-10 Pfeinsmith S.A. (Pty) Ltd Fulvic acid and antibiotic combination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225271A (en) 1987-07-08 1991-02-26 Nat Energy Council Oxidising coal using a gaseous oxidant
DE3903773A1 (de) 1988-02-11 1989-09-14 Nat Energy Council Eine mischung mit bakteriozider oder bakteriostatischer aktivitaet
US5204368A (en) 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
WO2000019999A1 (en) 1998-10-08 2000-04-13 Enerkom (Proprietary) Limited Fulvic acid and its use in the treatment of various conditions
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
WO2007125492A2 (en) * 2006-05-02 2007-11-08 Pfeinsmith S.A. (Pty) Ltd Acidic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147635A1 (en) * 2008-06-05 2009-12-10 Pfeinsmith S.A. (Pty) Ltd Fulvic acid and antibiotic combination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antibiotic-Resistant Bacteria Moving From South Asia to U.S. By Donald G. McNeil Jr. Перечень данных [он-лайн] 11.08.2010 [Найдено 18.10.2016] - найдено из Интернета: URL: http://www.nytimes.com/2010/08/12/world/asia/12bug.html?_r=2. *
В.А. Руднов. Антибиотикотерапия госпитальных инфекций, вызванных P. Aeruginosa. Русский медицинский журнал. Том 13, No 7. Перечень данных [он-лайн] 2005 г. [Найдено 18.10.2016] - найдено из Интернета: URL: http://medi.ru/doc/091125.htm. *
В.А. Руднов. Антибиотикотерапия госпитальных инфекций, вызванных P. Aeruginosa. Русский медицинский журнал. Том 13, No 7. Перечень данных [он-лайн] 2005 г. [Найдено 18.10.2016] - найдено из Интернета: URL: http://medi.ru/doc/091125.htm. Antibiotic-Resistant Bacteria Moving From South Asia to U.S. By Donald G. McNeil Jr. Перечень данных [он-лайн] 11.08.2010 [Найдено 18.10.2016] - найдено из Интернета: URL: http://www.nytimes.com/2010/08/12/world/asia/12bug.html?_r=2. *

Also Published As

Publication number Publication date
RU2014140227A (ru) 2016-04-27
EP2822551A1 (en) 2015-01-14
MY170829A (en) 2019-09-05
KR20140135813A (ko) 2014-11-26
IN2014DN07194A (enExample) 2015-04-24
WO2013132444A1 (en) 2013-09-12
CN104203227A (zh) 2014-12-10
US20150031767A1 (en) 2015-01-29
EP2822551B1 (en) 2016-12-21
US9265744B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
US20250170106A1 (en) Use of su3327 in preparation of medicament for enhancing efficacy of polymyxin against bacterial infection
CN108348453B (zh) 包含莫匹罗星及新霉素的抗微生物组合物
US20110319485A1 (en) Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori
RU2640928C2 (ru) Комбинация фульвовой кислоты и антибиотика для подавления роста бактерий, резистентных к множеству лекарственных средств, или лечения инфекций, вызванных ими
Goodyear et al. An improved selective culture medium enhances the isolation of Burkholderia pseudomallei from contaminated specimens
EP2317998B1 (en) Fulvic acid and antibiotic combination
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
Liu et al. Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo
CN114392253B (zh) 大蒜辣素在制备金属β-内酰胺酶抑制剂中的用途
WO2024187962A1 (zh) Su3327在制备降低多黏菌素细胞毒性和肾毒性的药物中的用途
US20120035125A1 (en) Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections
CN101816669B (zh) 一种含有庆大霉素和冰片的组合物及其应用
JP2012097072A (ja) 胃粘膜保護用組成物、ウレアーゼ活性阻害用組成物及びそれらの組成物を有効成分とする医薬製剤
CN115350197A (zh) 泽泻醇A-24-醋酸酯在提高MRSA对β-内酰胺类抗生素敏感性方面的应用
CN118846083B (zh) 后生元和绿原酸联用组合物及其应用
CN119157883B (zh) 一种抗菌剂及其制备方法
Amin Current techniques and future directions in antibiotic resistance breakers
Ibrahim Study the effect of Linum usitatissimum (flax seeds) and Eucalptus rostrata (Ecalyptus) leaves extracts on Pseudomonas aeruginosa growth in vivo and in vitro.
Maurizi Interplay between uropathogenic Escherichia coli and bladder cells and new strategies to counteract bacterial persistence
KR100630410B1 (ko) 생약추출물을 함유하는 여드름 예방 및 치료를 위한 외용제조성물
Avşar et al. Investigation of the Combinatorial Effects of Metformin and Selected Antibiotics on Klebsiella pneumoniae
Habila et al. Bile chemical substance from northern nigerian red goat inhibit microbes
WO2022138871A1 (ja) 皮膚疾患改善剤
Rindt et al. Biological impact of polyfloral honey on antibio-resistant Staphylococcus aureus isolated from canine dermatitis.
Dale et al. guinea pigs, the acute LD50's for sisomicin are between one-half

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20201015